Department of Medicine, University of Chicago, Chicago, IL, USA.
Future Oncol. 2013 Sep;9(9):1323-36. doi: 10.2217/fon.13.102.
Lung cancer is biologically aggressive and is the leading cause of cancer-related deaths. The development of lung cancer is unique in each patient according to clinical characterizations, prognosis, response and tolerance to treatment. Traditional capillary-based single-gene sequencing by a first-generation technique (known as Sanger sequencing) has been replaced by next-generation sequencing (NGS) since it allows massive parallel sequencing with lower cost and higher throughput. The NGS approach has made remarkable advances compared with traditional methods. We expect these methodologies to comprehensively interpret the global landscape of cancer and provide more information to fulfill the needs of personalized medicine. This review covers a brief introduction and summary on various NGS technologies, applications and important findings by NGS in lung cancer advances, including further discoveries in previously known target genes (EGFR, ALK and KRAS), the identification of additional lung cancer mutations and the global coordination of cancer genome studies.
肺癌具有很强的生物学侵袭性，是癌症相关死亡的主要原因。根据临床特征、预后、对治疗的反应和耐受性，每个患者的肺癌发展都是独特的。第一代技术（称为 Sanger 测序）的传统基于毛细血管的单基因测序已经被新一代测序（NGS）所取代，因为它可以以更低的成本和更高的通量进行大规模平行测序。与传统方法相比，NGS 方法取得了显著的进展。我们期望这些方法能够全面解读癌症的全球图谱，并提供更多信息，以满足个性化医疗的需求。这篇综述涵盖了对各种 NGS 技术的简要介绍和总结，以及 NGS 在肺癌进展中的应用和重要发现，包括先前已知靶基因（EGFR、ALK 和 KRAS）的进一步发现，额外的肺癌突变的鉴定以及癌症基因组研究的全球协调。
